Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
View stock

Stock highlights

Stock comparison highlights
Stock name
NexGelAbbVie
Last price
$3.79$294.45
Currency
USD
USD
$1.7M$521B
-50.79
-$15.00$5.81
0.810.19
0$6.83
02.35%
Sector
HealthHealth
Employees
1957,000
Ticker
$NXGL$ABBV
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $NXGL or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.